All News

2021

July

Media Release / Jul 21, 2021

Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.

Read More
Media Release / Jul 16, 2021

Sandoz launches first generic high dose intravenous iron, Ferumoxytol Injection, to treat US patients with iron deficiency anemia

Read More

June

Media Release / Jun 25, 2021

Sandoz announces EU launch of ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer

Read More

May

Media Release / May 18, 2021

Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe

Read More
Media Release / May 17, 2021

US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case

Read More
Media Release / May 03, 2021

Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine

Read More

April

Media Release / Apr 27, 2021

Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.

Read More

March

Media Release / Mar 16, 2021

Sandoz in-licenses brand and authorized generic of respiratory medicine Proventil® HFA (albuterol sulfate) Inhalation Aerosol from Kindeva Drug Delivery, with immediate generic availability in US

Read More

February

Media Release / Feb 11, 2021

Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics

Read More

January

Media Release / Jan 26, 2021

Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.

Read More